Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Satellite Symposia webcasts

ESMO-Asia-Virtual-Oncology-Week-1000x1000

Watch the webcasts from our industry partners Satellite Symposia

Navigating the therapeutic landscape of locally advanced/metastatic urothelial carcinoma (la/mUC)

Astellas

Watch session

  • Welcome & context setting
  • Therapeutic landscape of la/mUC progressing after 1st line therapy
  • Asian perspectives on la/mUC management in 2021
  • la/mUC case discussion: Platinum-eligible / Platinum-ineligible

Optimising treatment in ALK+ NSCLC: Debate and Ongoing Conversations

Pfizer Corporation Hong Kong Limited

Watch session

  • Welcome and introduction (published soon)
  • Expert debate: Management options in ALK+ NSCLC
  • Expert panel discussion: Discussing clinical evidences in ALK+ NSCLC from Asia and Q&A (published soon)
  • Closing remarks (published soon)

Expert Perspectives in Navigating the Evolving Treatment Landscape in Advanced NSCLC

Boehringer Ingelheim

Watch session

  • Opening and welcome remarks
  • A Strategic Approach to Select and Sequence Therapies in EGFRM+ NSCLC: Asia in Focus
  • Tackling Uncommon EGFR Mutations
  • The Role of EGFR-TKIs in the Treatment of Squamous NSCLC
  • LIVE Q&A

Transforming care in ER+ HER2- metastatic breast cancer with a focus on CDK4/6 inhibition

Pfizer Corporation Hong Kong Limited

Watch session

  • Welcome and introduction (published soon)
  • Optimizing management of ER+ HER2- mBC through Clinical & Real World Evidence
  • The Era of the Empowered mBC Patient
  • Experience sharing: clinical case presentation 1
  • Experience sharing: clinical case presentation 2
  • Q&A (published soon)
  • Closing remarks (published soon)

GI Cancers – I-O Regimens in the First Line and Beyond

Bristol Myers Squibb

Watch session

  • Welcome and introduction
  • I-O Therapies for Gastric Cancers: Moving Toward Earlier Treatment
  • The Expanding Role of I-O Therapies for Esophageal Cancer: Where Are We Today?
  • Practice Update – I-O Therapy in Colorectal Cancer

Navigating the new reality in HCC: take your seat for an open discussion

Ipsen

Watch session

  • Welcome and introduction
  • Treatment sequencing: a matter of fact?
  • Maximising efficacy and QoL: what can real-world cases teach us?
  • Join the conversation: live discussion and Q&A

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.